INmune Bio Inc [INMB] stock prices are down -4.85% to $5.30 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The INMB shares have gain 13.49% over the last week, with a monthly amount glided 8.16%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
INmune Bio Inc [NASDAQ: INMB] stock has seen the most recent analyst activity on October 21, 2024, when Alliance Global Partners initiated its Buy rating and assigned the stock a price target of $20. Previously, Raymond James started tracking the stock with Outperform rating on September 27, 2024, and set its price target to $18. On August 22, 2024, Scotiabank initiated with a Sector Outperform rating and assigned a price target of $22 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $16 on June 01, 2023. B. Riley Securities downgraded its rating to a Neutral and reduced its price target to $7 on May 24, 2022. Maxim Group reiterated a Buy rating for this stock on July 07, 2021, and upped its price target to $42. In a note dated April 21, 2021, B. Riley Securities initiated an Buy rating and provided a target price of $29 on this stock.
The stock price of INmune Bio Inc [INMB] has been fluctuating between $4.32 and $14.74 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. INmune Bio Inc [NASDAQ: INMB] shares were valued at $5.30 at the most recent close of the market. An investor can expect a potential return of 315.09% based on the average INMB price forecast.
Analyzing the INMB fundamentals
The INmune Bio Inc [NASDAQ:INMB] reported sales of 0.04M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -989.21%, Pretax Profit Margin comes in at -982.67%, and Net Profit Margin reading is -982.67%. To continue investigating profitability, this company’s Return on Assets is posted at -0.78, Equity is -1.16 and Total Capital is -1.07. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.11 points at the first support level, and at 4.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.60, and for the 2nd resistance point, it is at 5.91.
Ratios To Look Out For
It’s worth pointing out that INmune Bio Inc [NASDAQ:INMB]’s Current Ratio is 2.59. Further, the Quick Ratio stands at 2.59, while the Cash Ratio is 2.43. Considering the valuation of this stock, the price to sales ratio is 2937.84, the price to book ratio is 3.04.
Transactions by insiders
Recent insider trading involved Moss David J, Chief Financial Officer, that happened on Sep 30 ’24 when 10000.0 shares were purchased. President and CEO, Tesi Raymond Joseph completed a deal on Sep 12 ’24 to buy 15380.0 shares. Meanwhile, Chief Financial Officer Moss David J bought 7690.0 shares on Sep 12 ’24.
